CPC A61K 38/2073 (2013.01) [A61P 3/00 (2018.01); C07K 16/244 (2013.01); C12N 15/1136 (2013.01); A61K 39/3955 (2013.01)] | 8 Claims |
1. A method of treating a metabolic disease, comprising administering a therapeutically or prophylactically effective amount of an agent capable of inhibiting interleukin 11 (IL-11)-mediated signalling to a subject;
wherein the agent is selected from: (i) an anti-IL-11 antibody antagonist of IL-11-mediated signalling, or an antigen-binding fragment thereof, or (ii) an anti-IL-11Rα antibody antagonist of IL-11-mediated signalling, or an antigen-binding fragment thereof;
and wherein the metabolic disease is or comprises: obesity, being overweight, hyperglycaemia, pregnancy-associated hyperglycemia, insulin resistance, pre-diabetes, metabolic syndrome, hyperlipidaemia, hypertriglyceridemia, hypercholesterolemia, pancreatic insufficiency, pancreatitis, acute pancreatitis, chronic pancreatitis, lipotoxicity, or hyperglucagonemia.
|